Q-omics provides the consensus-scored MTBP profile across patient tissues and cancer cell-line models. MTBP expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MTBP is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, MTBP RNA expression shows 22,325 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where MTBP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTBP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTBP survival associations across molecular data types. MTBP RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTBP RNA expression–survival associations across cancer types. High MTBP expression shows unfavorable associations in ACC, LIHC, UVM, KIRP and MESO, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MTBP RNA expression.
This table summarizes MTBP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MTBP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTBP shows higher tumor expression in HNSC, BLCA, COAD, LUAD, KIRC and STAD. The HNSC box plot shows higher MTBP RNA expression in tumor versus normal tissue (log2 FC = +1.264, t-test p < 0.001).
This table shows molecular features associated with MTBP in patient tissues and cancer cell lines. In patient samples, MTBP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MTBP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
